Loading clinical trials...
Loading clinical trials...
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Conditions
Interventions
Induction Venetoclax
Maintenance Venetoclax
Locations
10
United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, Maryland, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Rutgers Cancer Institute of NJ
New Brunswick, New Jersey, United States
Fox Chase
Philadelphia, Pennsylvania, United States
Start Date
December 27, 2017
Primary Completion Date
May 3, 2021
Completion Date
January 6, 2023
Last Updated
May 23, 2025
NCT07545603
NCT06337318
NCT05006716
NCT06026319
NCT06510361
NCT07128641
Lead Sponsor
PrECOG, LLC.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions